A prospective study on the differential association of sarcopenia and frailty with health outcomes in cirrhotic patients

Dig Liver Dis. 2023 Nov;55(11):1533-1542. doi: 10.1016/j.dld.2023.07.007. Epub 2023 Jul 21.

Abstract

Background: To investigate the joint impact of sarcopenia and frailty on mortality and the development of decompensation in cirrhosis.

Methods: Sarcopenia was assessed using the skeletal muscle mass index (SMI) by computed tomography, whereas frailty was measured using the Fried Frailty Phenotype (FFP). Cox proportional hazard regression and competing risks analysis were used to evaluate their association with adverse outcomes.

Results: The prevalence of sarcopenia and frailty was 29.6% and 37.2%, respectively. Sarcopenia and frailty separately increased more than two times higher risk of all-cause mortality after adjustment for age, gender, Child-Turcotte-Pugh, and comorbidities. Co-occurrence of sarcopenia and frailty was associated with a higher incremental risk of mortality in patients with cirrhosis (HR = 4.16, 95% CI: 1.64-10.58, P = 0.003), but these two conditions didn't have significant interaction. Frailty, but not sarcopenia, was significantly associated with an increased cumulative incidence of liver-related mortality and decompensation after adjusting covariates. Subgroup analysis revealed that frailty shortened the liver-related survival of cirrhosis patients with male or higher liver severity based on MELD.

Conclusions: Co-occurrence of sarcopenia and frailty increased the risk of death in cirrhosis, but these two conditions didn't have a significant interaction association. Frailty, but not sarcopenia, was associated with more adverse outcomes in cirrhotic patients.

Keywords: Cirrhosis; Frailty; Prognostic factor; Sarcopenia.

MeSH terms

  • Frailty* / epidemiology
  • Humans
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / epidemiology
  • Male
  • Outcome Assessment, Health Care
  • Prospective Studies
  • Sarcopenia* / etiology